Science Explorer Back to mapMap
Discussion
Researcher · Illinois CancerCare · United States

Gregory James Gerstner

Gregory James Gerstner publishes mostly in Oncology, Pulmonary and Respiratory Medicine and Immunology, on topics such as Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations and Lung Cancer Research Studies.

ORCID 0009-0008-3072-7901 OpenAlex
World rank
#1,835,579
of 7,710,434 ranked researchers
Rank in United States
#562,965
of 1,627,098
Works
60
Citations
666
Citations per work
11.1
h-index
10
i10-index 10Top 59% in Oncology
Gregory James Gerstner

What does Gregory James Gerstner research?

Gregory James Gerstner's work is mostly in Medicine (51%), Immunology and Microbiology (8%), Biochemistry, Genetics and Molecular Biology (5%).

Health Sciences: 30 works · 50.7% of their workMedicine: 30 works · 50.7% of their workOncology: 17 works · 27.8% of their workPulmonary and Respiratory Medicine: 8 works · 12.7% of their workGenetics: 3 works · 5.1% of their workHematology: 3 works · 5.1% of their workEverything else: 22 works · 36.6% of their workLife Sciences: 8 works · 12.7% of their workImmunology and Microbiology: 5 works · 7.6% of their workImmunology: 5 works · 7.6% of their workBiochemistry, Genetics and Molecular Biology: 3 works · 5.1% of their workBiotechnology: 3 works · 5.1% of their workTHEIR WORKGregory JamesGerstner60works
Life Sciences13%Health Sciences51%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
    1. Medicine3050.7%
  2. Everything else2236.6%
    1. Immunology and Microbiology57.6%
    2. Biochemistry, Genetics and Molecular Biology35.1%
  1. 1Oncology28% of their works
  2. 2Pulmonary and Respiratory Medicine13% of their works
  3. 3Immunology8% of their works
  4. 4Hematology5% of their works
  5. 5Genetics5% of their works
  6. 6Biotechnology5% of their works

Research topics

Which keywords describe Gregory James Gerstner's research?

The keywords of their largest research topics: Targeted Therapy, Clinical Trials, Chemotherapy, Immunotherapy, Immune Checkpoint Blockade, PD-1 and PD-L1, ALK Inhibitors and EGFR Mutations.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 20 words, with their numbers
  1. Targeted Therapy143 topics
  2. Clinical Trials122 topics
  3. Chemotherapy113 topics
  4. Immunotherapy92 topics
  5. Immune Checkpoint Blockade81 topic
  6. PD-1 and PD-L181 topic
  7. ALK Inhibitors71 topic
  8. EGFR Mutations71 topic
  9. Genomic Profiles51 topic
  10. Small-Cell Lung Cancer51 topic
  11. Bacterial Therapy41 topic
  12. Dendritic Cells41 topic
  13. Immunity41 topic
  14. Tumor Targeting41 topic
  15. CT Screening31 topic
  16. Cetuximab31 topic
  17. KRAS Mutations31 topic
  18. Lung Cancer31 topic
  19. Cancer Genomics21 topic
  20. Mutational Signatures21 topic

Where does Gregory James Gerstner work?

Gregory James Gerstner's main affiliation in the publication record is Illinois CancerCare, United States.

How many publications and citations does Gregory James Gerstner have?

OpenAlex counts 60 works and 666 citations for Gregory James Gerstner, an h-index of 10, ranking #1,835,579 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about Gregory James Gerstner. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.